Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varlilumab + Ipilimumab +/- CDX-1401 in Melanoma
NCT02413827Phase 2Terminated
- Sponsor
- Celldex Therapeutics
- Start
- Apr 2015
- Primary completion
- Nov 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of varlilumab in melanoma, sponsored by Celldex Therapeutics. Started Apr 2015; status: terminated.
02
Drugs
varlilumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02413827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02413827.